Thus, the fact that NfL serum or plasma levels seem likely to reflect the axonal loss of LMNs in ALS patients supports the idea that NfL levels will perform well with regard to predicting disease progression and survival. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.